Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.80 |
| ▸ | EGFR | P00533 | 10/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11948689 | 0.89 | METTL3 (0.64) | METTL3MAPT | |
| Elvitegravir SCHEMBL726252 | 0.89 | METTL3 (1.00) | METTL3EGFRPLA2G4AGAATP53 | |
| Elvitegravir SCHEMBL29623981 | 0.89 | METTL3 (1.00) | METTL3EGFRPLA2G4AGAATP53 | |
| Elvitegravir SCHEMBL726251 | 0.89 | METTL3 (1.00) | METTL3EGFRPLA2G4AGAATP53 | |
| SCHEMBL1104875 | 0.89 | METTL3 (0.88) | METTL3EGFRPLA2G4AGAAMAPT | |
| Elvitegravir SCHEMBL13225651 | 0.89 | METTL3 (1.00) | METTL3EGFRPLA2G4AGAATP53 | |
| SCHEMBL19829420 | 0.89 | METTL3 (0.88) | METTL3EGFRPLA2G4AGAAMAPT | |
| SCHEMBL13862207 | 0.89 | METTL3 (0.64) | METTL3EGFRPLA2G4AGAACNR2 | |
| SCHEMBL13693054 | 0.88 | METTL3 (0.86) | METTL3EGFRPLA2G4AGAATP53 | |
| SCHEMBL13942147 | 0.88 | METTL3 (0.86) | METTL3EGFRPLA2G4AGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183472-A1 | ANTIVIRAL PRODRUGS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-09-28 | — | — | WO | disclosed |